Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research 2022 Annual Meeting
PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from preclinical
Source: finanznachrichten.de